BIOAVAILABILITY ENHANCEMENT OF REPAGLINIDE USING NANO LIPID CARRIER: PREPARATION CHARACTERIZATION & IN-VIVO EVALUATION

Authors

  • ROOHI KESHARWANI Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Naini, Prayagraj, U. P., India https://orcid.org/0000-0001-8764-6207
  • DILIP K. PATEL Department of Pharmacy, Government Polytechnic Jaunpur, U. P. India
  • PANKAJ KUMAR YADAV Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Naini, Prayagraj, U.P., India

DOI:

https://doi.org/10.22159/ijap.2022v14i5.45032

Keywords:

Repaglinide, Nanostructure Lipid Carreir, NLC, SLN, Solid Lipid Nanoparticle, Lipid nanoparticle

Abstract

Objective:  The aim of this study to manufacture the prolonged release lipid nanoparticle (Solid lipid nanoparticle and nanostructure lipid carrier) of repaglinide for enhance the oral bioavailability.

Methods: Solid lipid nanoparticle (SLN) and  Nanostructured lipid carrier (NLC) were prepared by slight modification in solvent diffusion method. The core material used as cetyl alcohol while blend with oleic acid were used in preparation of NLC dispersion. Tween 80 were utilized as Surfactant and lecithin as cosurfactant in both type of lipid formulation. Lipid nanoparticle were characterized for size distribution, entrapment parameter, zeta potential, surface morphology, in-vitro drug release and stability study. Pharmacodynamic study were also performed to evaluate the antidiabetic activity of repaglinide loaded lipid nano dispersion.

Results: It was observed that lipid matrix based SLN and NLC having significant particle size (157.8±15.8nm for NLC and 238.4± 48.2nm for SLN dispersion), entrapment efficacy 79.82±0.84% for NLC and 72.04±1.03% for SLN dispersion. Zeta potential report were also clarifying that formulation is in stable state for a prolong time. SEM study size distribution of particle as evaluated by Malvern instrument. The formulation was also confirmed to be stable after 180 days of storage, according to the data from the stability study. The in vivo antidiabetic assessment showed that Repaglinide loaded SLN and NLC dispersion were able to reduce the blood sugar level. Interestingly, in case of the RPG-SLN, RPG-NLC-I & RPG-NLC-II group, and the average blood sugar values at all time intervals were significantly less than that of the basal glucose value (p< 0.05).

Conclusion: The prepared SLN and NLC dispersion having ability to control the release and make nano formulation suitable to resolve poor bioavailability of repaglinide.

Downloads

Download data is not yet available.

Author Biography

ROOHI KESHARWANI, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Naini, Prayagraj, U. P., India

Assistant professor

References

Poonia N, Kharb R, Lather V, Pandita D. Nanostructured lipid carriers: versatile oral delivery vehicle. Future Sci OA. 2016;2(3).

Patel P, Patel M. Nanostructured Lipid Carriers- A Versatile Carrier for Oral Delivery of Lipophilic Drugs. Recent Patents on Nanotechnology. 2020 Sep 10;15(2):154–64.

Gaba B, Fazil M, Ali A, Baboota S, Sahni JK, Ali J. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Delivery. 2015 Aug 18;22(6):691–700.

Banerjee S, Pillai J. Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs. Expert Opinion on Drug Metabolism and Toxicology. 2019 Jun 3;15(6):499–515.

Pathak K, Raghuvanshi S. Oral bioavailability: issues and solutions via nanoformulations. Clin Pharmacokinet. 2015 Mar 21;54(4):325–57.

Zhang L, Wang S, Zhang M, Sun J. Nanocarriers for oral drug delivery. Journal of Drug Targeting. 2013 Jul;21(6):515–27.

Ebrahimi HA, Javadzadeh Y, Hamidi M, Jalali MB. Repaglinide-loaded solid lipid nanoparticles: effect of using different surfactants/stabilizers on physicochemical properties of nanoparticles. DARU Journal of Pharmaceutical Sciences. 2015 Sep 21;23(1).

Culy CR, Jarvis B. Repaglinide: A review of its therapeutic use in type 2 diabetes mellitus. Drugs. 2001;61(11):1625–60.

Lokhande AB, Mishra S, Kulkarni RD, Naik JB. Preparation and characterization of repaglinide loaded ethylcellulose nanoparticles by solvent diffusion technique using high pressure homogenizer. Journal of Pharmacy Research. 2013 May;7(5):421–6.

Tripathi K. Essentials of Medical Pharmacology. Essentials of Medical Pharmacology. 2008;

Rawat MK, Jain A, Singh S. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats. J Pharm Sci. 2011 Jun;100(6):2406–17.

Jain S, Saraf S. Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. J Diabetes. 2009;1(1):29–35.

Tavakoli N, Minaiyan M, Tabbakhian M, Pendar Y. Preparation and evaluation of a controlled drug release of repaglinide through matrix pellets: in vitro and in vivo studies. J Microencapsul. 2014;31(6):529–34.

Pandey SS, Patel MA, Desai DT, Patel HP, Gupta AR, Joshi S V., Shah DO, Maulvi FA. Bioavailability enhancement of repaglinide from transdermally applied nanostructured lipid carrier gel: Optimization, in vitro and in vivo studies. Journal of Drug Delivery Science and Technology. 2020 Jun 1;57:101731.

Vijayan V, Reddy KR, Sakthivel S, Swetha C. Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: In vitro and in vivo studies. Colloids and Surfaces B: Biointerfaces. 2013 Nov 1;111:150–5.

Patel DK, Kumar V, Kesharwani R. Lipid nanoparticle topical & transdermal delivery: a review on production, penetration mechanism to skin. Current Nanomedicine. 2019;

Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Vol. 366, International Journal of Pharmaceutics. 2009. p. 170–84.

Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2000.

Patel DK, Tripathy S, Nair SK, Kesharwani R. Nanostructured lipid carrier (NLC) a modern approach for topical delivery: a review. World J Pharm Pharma Sci. 2013;

Patel DK, Kesharwani R, Kumar V. Etodolac loaded solid lipid nanoparticle based topical gel for enhanced skin delivery. Biocatalysis and Agricultural Biotechnology. 2020;

Patel DK, Kesharwani R, Kumar V. Lipid Nanoparticle Topical and Transdermal Delivery: A Review on Production, Penetration Mechanism to Skin. International Journal of Pharmaceutical Investigation. 2019;

Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Vol. 366, International Journal of Pharmaceutics. 2009. p. 170–84.

Kesharwani R, Sachan A, Singh S, Patel D. Formulation and Evaluation of Solid Lipid Nanoparticle (SLN) Based Topical Gel of Etoricoxib. Journal of Applied Pharmaceutical Science. 2016;124–31.

Patel DK, Kesharwani R, Al-Abbasi FA, Anwar F, Kumar V. Topical Nanostructured Lipid Carrier (NLC) gel of Etodolac: Central Composite Design, Optimization, In Vitro Skin Penetration and Dermatokinetic Study.

Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Vol. 71, Indian Journal of Pharmaceutical Sciences. 2009. p. 349–58.

Gaba B, Fazil M, Ali A, Baboota S, Sahni JK, Ali J. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Vol. 22, Drug Delivery. Taylor and Francis Ltd; 2015. p. 691–700.

Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;

Wu L, Zhao L, Su X, Zhang P, Ling G. Repaglinide-loaded nanostructured lipid carriers with different particle sizes for improving oral absorption: preparation, characterization, pharmacokinetics, and in situ intestinal perfusion. Drug Deliv. 2020;27(1):400–9.

Swidan SA, Ghonaim HM, Samy AM, Ghorab MM. Efficacy and In Vitro Cytotoxicity of Nanostructured Lipid Carriers for Paclitaxel Delivery ARTICLE INFO ABSTRACT. Journal of Applied Pharmaceutical Science. 2016;6(09):18–026.

Shi F, Wei Z, Zhao Y, Xu X. Nanostructured Lipid Carriers Loaded with Baicalin: An Efficient Carrier for Enhanced Antidiabetic Effects. Pharmacogn Mag. 2016 Jul 1;12(47):198–202.

Maity S, Mukhopadhyay P, Kundu PP, Chakraborti AS. Alginate coated chitosan core-shell nanoparticles for efficient oral delivery of naringenin in diabetic animals-An in vitro and in vivo approach. Carbohydr Polym. 2017 Aug 15;170:124–32.

Deshkar S, Quazi N, Patil A, Poddar S. Effect of Gelucire 44/14 on Fluconazole Solid Lipid Nanoparticles: Formulation, Optimization and in vitro Characterization. Drug Delivery Letters. 2016 Apr 7;5(3):173–87.

Mazumder S, Dewangan AK, Pavurala N. Enhanced dissolution of poorly soluble antiviral drugs from nanoparticles of cellulose acetate based solid dispersion matrices. Asian Journal of Pharmaceutical Sciences. 2017 Nov 1;12(6):532–41.

KHARWADE RS, MAHAJAN NM. FORMULATION AND EVALUATION OF NANOSTRUCTURED LIPID CARRIERS BASED ANTI-INFLAMMATORY GEL FOR TOPICAL DRUG DELIVERY SYSTEM. Asian Journal of Pharmaceutical and Clinical Research. 2019 Apr 7;12:286–91.

Jahangir MA, Khan R, Sarim Imam S. Formulation of sitagliptin-loaded oral polymeric nano scaffold: process parameters evaluation and enhanced anti-diabetic performance. Artif Cells Nanomed Biotechnol. 2018 Oct 31;46(sup1):66–78.

Lokhande A, Mishra S, Kulkarni R, Naik J. Development and Evaluation of Nateglinide Loaded Polycaprolactone Nanoparticles. Micro and Nanosystems. 2015 Jun 28;7(1):43–8.

Yuan H, Wang LL, Du YZ, You J, Hu FQ, Zeng S. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf B Biointerfaces. 2007 Nov 15;60(2):174–9.

Czajkowska-Kośnik A, Szymańska E, Czarnomysy R, Jacyna J, Markuszewski M, Basa A, Winnicka K. Nanostructured Lipid Carriers Engineered as Topical Delivery of Etodolac: Optimization and Cytotoxicity Studies. Materials (Basel). 2021 Feb 1;14(3):1–21.

Dhome AG, Deshkar SS, Shirolkar S V. Gliclazide Solid Lipid Nanoparticles: Formulation, Optimization and in Vitro Characterization. Pharmaceutical Resonance. 2018;1:1.

Rawat MK, Jain A, Singh S. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation. J Pharm Sci. 2011 Jun;100(6):2366–78.

Date AA, Vador N, Jagtap A, Nagarsenker MS. Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery. Nanotechnology. 2011 Jul 8;22(27).

Teeranachaideekul V, Müller RH, Junyaprasert VB. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-Effects of formulation parameters on physicochemical stability. International Journal of Pharmaceutics. 2007;

El-Housiny S, Eldeen MAS, El-Attar YA, Salem HA, Attia D, Bendas ER, El-Nabarawi MA. Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: Formulation and clinical study. Drug Delivery. 2018;25(1).

Westesen K, Bunjes H, Koch MHJ. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. Journal of Controlled Release. 1997;48(2–3).

Purvis T, Mattucci ME, Crisp MT, Johnston KP, Williams RO. Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process. AAPS PharmSciTech. 2007 Jul 20;8(3).

Kassem AA, Abd El-Alim SH, Basha M, Salama A. Phospholipid complex enriched micelles: A novel drug delivery approach for promoting the antidiabetic effect of repaglinide. Eur J Pharm Sci. 2017 Mar 1;99:75–84.

Müller RH, Runge SA, Ravelli V, Thünemann AF, Mehnert W, Souto EB. Cyclosporine-loaded solid lipid nanoparticles (SLN®): Drug-lipid physicochemical interactions and characterization of drug incorporation. European Journal of Pharmaceutics and Biopharmaceutics. 2008;68(3).

Marquele-Oliveira F, de Almeida Santana DC, Taveira SF, Vermeulen DM, Moraes de Oliveira AR, da Silva RS, Lopez RFV. Development of nitrosyl ruthenium complex-loaded lipid carriers for topical administration: improvement in skin stability and in nitric oxide release by visible light irradiation. Journal of Pharmaceutical and Biomedical Analysis. 2010;53(4).

Mohseni R, ArabSadeghabadi Z, Ziamajidi N, Abbasalipourkabir R, RezaeiFarimani A. Oral Administration of Resveratrol-Loaded Solid Lipid Nanoparticle Improves Insulin Resistance Through Targeting Expression of SNARE Proteins in Adipose and Muscle Tissue in Rats with Type 2 Diabetes. Nanoscale Research Letters. 2019;14(1).

Vijayakumar MR, Kumari L, Patel KK, Vuddanda PR, Vajanthri KY, Mahto SK, Singh S. Intravenous administration of: Trans -resveratrol-loaded TPGS-coated solid lipid nanoparticles for prolonged systemic circulation, passive brain targeting and improved in vitro cytotoxicity against C6 glioma cell lines. RSC Advances. 2016;6(55).

Siepmann J, Siepmann F. Mathematical modeling of drug delivery. Vol. 364, International Journal of Pharmaceutics. 2008.

Ebrahimi HA, Javadzadeh Y, Hamidi M, Jalali MB. Repaglinide-loaded solid lipid nanoparticles: Effect of using different surfactants/stabilizers on physicochemical properties of nanoparticles. DARU, Journal of Pharmaceutical Sciences. 2015;23(1).

Published

04-07-2022

How to Cite

KESHARWANI, R., PATEL, D. K., & YADAV, P. K. (2022). BIOAVAILABILITY ENHANCEMENT OF REPAGLINIDE USING NANO LIPID CARRIER: PREPARATION CHARACTERIZATION & IN-VIVO EVALUATION. International Journal of Applied Pharmaceutics, 14(5). https://doi.org/10.22159/ijap.2022v14i5.45032

Issue

Section

Original Article(s)